University of Turin-ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2022

  1. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)

    Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1404-1414

2020

  1. Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) – A decision-making analysis amongst European lung cancer experts

    Lung Cancer, Vol. 146, pp. 6-11

  2. Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts

    Radiotherapy and Oncology, Vol. 149, pp. 84-88

2019

  1. Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts

    Radiotherapy and Oncology, Vol. 135, pp. 74-77

  2. Erratum to “Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts” [Radiother. Oncol. 135 (2019) 74–77](S0167814019300775)(10.1016/j.radonc.2019.02.010)

    Radiotherapy and Oncology

  3. Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts

    Radiotherapy and Oncology, Vol. 133, pp. 163-166

2018

  1. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

    The Lancet Respiratory Medicine, Vol. 6, Núm. 10, pp. 771-781

2017

  1. Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: Results by age subgroup

    ESMO Open

2015

  1. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC)

    Lung Cancer, Vol. 88, Núm. 2, pp. 160-166